Acura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain
February 05, 2015 06:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - February 05, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the launch of their second pseudoephedrine (PSE) product, NEXAFED® Sinus Pressure +...
Acura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
January 08, 2015 06:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - January 08, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that the Company has entered into a Collaboration and License Agreement (the...
Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
December 23, 2014 06:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - December 23, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine...
Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
December 08, 2014 06:30 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, ILL--(Marketwired - December 08, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has...
Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results
November 03, 2014 16:30 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - November 03, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse,...
Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014
October 28, 2014 11:11 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - October 28, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company...
Acura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets Development
October 16, 2014 06:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - October 16, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today that the US Food and Drug Administration (FDA) has denied on procedural grounds Acura's...
Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints
September 29, 2014 06:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - Sep 29, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION®...
Acura Pharmaceuticals Submits Formal Dispute Resolution Request With FDA Regarding Hydrocodone Bitartrate With Acetaminophen Tablets
September 15, 2014 06:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - Sep 15, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has submitted a formal dispute resolution request with the FDA for Vycavert®,...
Acura Pharmaceuticals Receives Grant From National Institutes of Health to Fund Limitx(TM) Novel Abuse Deterrent Technology
August 27, 2014 06:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - Aug 27, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has been awarded a $300,000 grant (the "Grant") by the National Institute On Drug...